Business Wire

Helfie AI Collaborates With Microsoft to Offer AI-Powered Mobile Platform to Microsoft Enterprise Customers

Share

Helfie AI also joins Microsoft for Startups Pegasus Program for high-potential startups

Helfie AI (“the Company” or “Helfie”), a global mobile health platform, has collaborated with Microsoft to offer Microsoft enterprise customers the ability to license Helfie’s cutting-edge health assessment tools directly through Microsoft Azure Marketplace. Helfie, which has the potential to achieve unicorn status, has also been accepted into the highly selective Microsoft for Startups Pegasus program, which is reserved for a small handful of startups with established product-market fit.

The Microsoft relationship marks a significant milestone in Helfie’s mission to revolutionize global healthcare access and participation. Helfie is a ground-breaking mobile platform powered by artificial intelligence that enables anyone with a smartphone anywhere in the world to check for a range of health conditions quickly and accurately with the support of health professionals. Helfie’s AI mobile platform is developed using extensive clinical datasets that result in its health assessment tools typically providing over 90% accuracy when checking for health conditions. The Company’s suite of products, including Vitals AI, Respiratory AI, STI AI, and Skin AI, harness multi-modal AI algorithms to analyze images, videos, and sound recordings for quick and accurate health assessments.

The collaboration provides Microsoft enterprise customers with the opportunity to gain streamlined access to check for health conditions, and the ability to quickly set up and integrate Helfie's AI-powered healthcare solutions within existing Microsoft environments. By utilizing Microsoft's dedicated NDm A100 v4-series GPU cluster in Azure Machine Learning, Helfie has achieved a remarkable reduction in its AI model training time from two weeks to just two hours. This marks a major step forward in the accessibility of advanced health tech for large organizations that enable them to provide their employees with tools to identify health concerns earlier and promote a healthier lifestyle.

"Collaborating with Microsoft has been instrumental in the accelerated development and scaling of our capabilities,” said Nikhil Sehgal, CTO of Helfie AI. “The drastic reduction in model training time has been critical to building faster and getting our product into the hands of users as part of our ambition to democratize access to healthcare through AI-powered mobile checks. The ability for Microsoft customers to license our solution directly through Microsoft Azure Marketplace is a game-changer for large-scale adoption of our technology.”

“Joining the Microsoft for Startups Pegasus Program is a testament to Helfie AI’s innovation and impact in transforming how we approach health assessments on a global scale,” said Tom Davis, Partner at Microsoft for Startups. “We’re pleased to see Helfie use Microsoft’s cloud and AI capabilities to accelerate their mission and provide our enterprise customers with a powerful, easily accessible tool that empowers individuals to take proactive measures to be better informed about their health.”

The Microsoft for Startups Pegasus program is an exclusive initiative designed to propel high-potential startups towards unicorn status. The program was launched by Microsoft just over a year ago, and it provides selected startups with extensive resources, including Azure credits, Go-to-Market support, technical resources, and unique benefits such as access to Azure AI infrastructure on dedicated GPU clusters.

“Helfie has been a part of Microsoft’s Founder’s Hub for quite some time, so to be invited to participate in the Pegasus program means we’ve proven that there is a significant need worldwide for our mobile platform and that we’ve delivered on the promise of our technology,” George Tomeski, CEO of Helfie AI. “Through our relationship with Microsoft, we are continuing to provide access to affordable health assessment tools with an accuracy that is backed by data science.”

Several of Helfie AI's products are now available on the Azure Marketplace, with direct licensing options for Microsoft enterprise customers.

About Helfie AI

Helfie AI was founded in Melbourne, Australia, in 2021 and has expanded operations to Europe, North America, Africa and Asia with multiple active B2B partnerships with top tier companies already in place.

Helfie AI tackles two of healthcare's most fundamental challenges: the lack of participation in preventative healthcare and the under-utilisation of health data. Every facet of healthcare, starting with the quality and longevity of human life, can be dramatically improved if everyone actively participates in preventative health and if health data is actively utilized throughout the healthcare system.

The accessibility made possible by Helfie AI can significantly reduce the $7 trillion spent annually on treating preventable conditions.

Helfie AI's advanced AI technologies analyse pictures, videos, sound recordings or face scans to check for indications of potential health conditions. Helfie AI generates instant results and offers the user information and options on what to do next. Importantly, the user owns and controls all of the data provided as part of the checks.

More details on the checks Helfie can make are available at www.helfie.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030026596/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials, Accelerating Study Design and Execution31.10.2024 13:00:00 CET | Press release

New offerings combine a variety of Medidata technologies and learnings from thousands of previous trials to streamline study management for Phase II and Phase III studies in specified therapeutic areas, reinforcing FDA guidance for patient-centered study design and execution Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has introduced two new bundled offerings to meet the growing demands of oncology and vaccine research. Medidata Oncology Solutions and Medidata Vaccine Solutions reinforce the FDA guidance for patient-centered endpoints, adaptive trial designs, and trial diversity. By unifying key trial components such as real-time patient-reported outcomes and imaging management, these bundled solutions will aid sponsors by reducing trial complexity, accelerating decision-making, and improving assessments of treatment efficacy and safety. "Oncology and vaccine trials face significant challenges in recruiting diverse

Hassana Investment Company and EIG Sign MoU for Strategic Collaboration on Middle East Infrastructure and Energy Transition Projects31.10.2024 13:00:00 CET | Press release

Collaboration advances shared objectives for investment in the Kingdom of Saudi Arabia and the rest of the region with EIG’s targeted US$1 billion dedicated regional fund Hassana Investment Company (Hassana) and EIG, a leading institutional investor to the global energy and infrastructure sectors, have signed a memorandum of understanding (MoU) to collaborate on infrastructure and energy transition projects in the Middle East through EIG’s targeted US$1 billion dedicated regional fund in which Hassana is considering becoming an anchor investor with an allocation of up to US$250 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241029142798/en/ (Photo: Business Wire) The MoU underscores EIG’s and Hassana’s shared commitment to expand their local and regional infrastructure and energy transition investment portfolios. By fostering participation from international investors and boosting foreign direct investment, this par

Kinaxis Announces Normal Course Issuer Bid31.10.2024 12:00:00 CET | Press release

Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “Exchange” or “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the Company may, during the 12-month period commencing November 6, 2024 and ending November 5, 2025, or on such earlier date as Kinaxis completes its purchases or provides notice of termination, purchase up to 1,404,639 Shares in total, representing approximately 5% of the issued and outstanding Shares as at October 23, 2024. As of the close of business on October 23, 2024, the Company had 28,092,786 Shares issued and outstanding. Except for block purchases permitted under the rules of the TSX, the number of Shares to be

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates31.10.2024 11:30:00 CET | Press release

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025COMP006 data will now be announced after 26-week time point, expected in the second half of 2026Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30%Cash position of $207 millionConference call October 31 at 8:00 am ET (12:00 pm UK) Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progress. “Ensuring the success of our lead COMP360 program is our absolute priority. We remain confident that COMP360 can be an effective therapy for patients with serious mental illness and our focus on delivering new treatment options for patients living with treatment-resistant depression remains paramount,” said Kab

DriveWealth Advances Global Expansion Plans with European Brokerage License from Bank of Lithuania31.10.2024 11:00:00 CET | Press release

Lithuania will become DriveWealth’s base of operations for its European brokerage partners with plans to expand the team based in Lithuania DriveWealth, a leading financial technology platform providing Brokerage-as-a-Service, today announced that the Bank of Lithuania, the central bank of the Republic of Lithuania, granted it a brokerage license in Europe. This license accelerates DriveWealth’s international expansion and marks its third region with regulatory status, including the United States, Singapore, and now the European Economic Area. DriveWealth powers modern investing experiences, including 24-hour trading and fractional share ownership, for a community of global B2B partners. Securing this license supports DriveWealth’s ability to expand its platform to offer European securities as well as provide a “follow-the-sun” 24/7 service model continuously across time zones. The new entity in Lithuania, named DriveWealth Europe, will be an integral component of DriveWealth’s interna

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye